Back to top

Image: Shutterstock

Zacks.com featured highlights include Sanderson Farms, United Therapeutics, AMN Healthcare

Read MoreHide Full Article

For Immediate Release

Chicago, IL – June 27, 2022 – Stocks in this week’s article are Sanderson Farms, Inc. , United Therapeutics Corp. (UTHR - Free Report) and AMN Healthcare Services, Inc. (AMN - Free Report) .

Buy These 3 Low-Beta Stocks to Sail Through a Choppy Market

The market is fearing recession since the Federal Reserve is committed to combating inflation at all costs while tightening monetary policy. The market will possibly be choppy since most of the analysts are of the view that economic activity is cooling.

Hence, creating a portfolio of low-beta stocks is of utmost importance since the securities will deliver healthy returns and provide a shield against volatile market conditions. In this regard, stocks like Sanderson Farms, Inc., United Therapeutics Corp. and AMN Healthcare Services, Inc. are worth betting on.

Beta Understanding

Beta measures the volatility or risk of a particular asset compared to the market. In other words, beta measures the extent of a security's price movement relative to the market. In this article, we are considering the S&P 500 as the market.

If a stock has beta of 1, then the price of the stock will move with the market. So, the stock is more volatile than the market if its beta is more than 1. In the same way, the stock is not as volatile as the market if its beta is less than 1.

For example, if the market offers a return of 20%, a stock with beta of 3 will return 60%, which is overwhelming. Similarly, when the market slips 20%, the stock will sink 60%, which is devastating.

Here are three stocks among five that qualified the screening:

Sanderson Farms secures stable cashflows from producing, processing and distributing fresh, frozen and minimally prepared chicken. Backed by higher average selling prices, Sanderson Farms is experiencing increased margins. For fiscal 2022, Sanderson Farms has experienced increased earnings estimate revisions over the past 30 days.

United Therapeutics has been focusing on finding ways to cure diseases like pulmonary arterial hypertension and several life-threatening illnesses. In this mission, United Therapeutics has gained approvals from FDA for five medicines. Overall, the company's prospects are bright on the back of its aim of creating manufactured organs at a massive scale for transplantation.

AMN Healthcare Services, a leader in total talent solutions for healthcare organizations, recently pleased shareholders with the announcement of a $250 million share repurchase program. The portfolio of AMN Healthcare's diversified solutions is in great demand since healthcare organizations are still facing a massive shortage of labor. In the past 60 days, AMN Healthcare has witnessed upward earnings estimate revisions for 2022 earnings.

You can get the rest of the stocks on this list by signing up now for your 2-week free trial to the Research Wizard and start using this screen in your own trading. Further, you can also create your own strategies and test them first before taking the investment plunge.

The Research Wizard is a great place to begin. It's easy to use. Everything is in plain language. And it's very intuitive. Start your Research Wizard trial today. And the next time you read an economic report, open up the Research Wizard, plug your finds in, and see what gems come out.

Click here to sign up for a free trial to the Research Wizard today.

For the rest of this Screen of the Week article please visit Zacks.com at: https://www.zacks.com/stock/news/1943380/buy-these-3-low-beta-stocks-to-sail-through-a-choppy-market

Disclosure: Officers, directors and/or employees of Zacks Investment Research may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material. An affiliated investment advisory firm may own or have sold short securities and/or hold long and/or short positions in options that are mentioned in this material.

About Screen of the Week

Zacks.com created the first and best screening system on the web earning the distinction as the "#1 site for screening stocks" by Money Magazine.  But powerful screening tools is just the start. That is why Zacks created the Screen of the Week to highlight profitable stock picking strategies that investors can actively use.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has more than doubled the market from 1988 through 2016. Its average gain has been a stellar +25% per year. See these high-potential stocks free >>.

Follow us on Twitter:  https://www.twitter.com/zacksresearch

Join us on Facebook:  https://www.facebook.com/ZacksInvestmentResearch

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Contact: Jim Giaquinto

Company: Zacks.com

Phone: 312-265-9268

Email: pr@zacks.com

Visit: https://www.zacks.com/

Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performancefor information about the performance numbers displayed in this press release.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


United Therapeutics Corporation (UTHR) - free report >>

AMN Healthcare Services Inc (AMN) - free report >>

Published in